- Home
- VTYX vs OPRX Comparison
VTYX vs OPRX Comparison
Compare VTYX & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- OPRX
- Stock Information
- Founded
- VTYX 2018
- OPRX 2006
- Country
- VTYX United States
- OPRX United States
- Employees
- VTYX N/A
- OPRX N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- OPRX Business Services
- Sector
- VTYX Health Care
- OPRX Consumer Discretionary
- Exchange
- VTYX Nasdaq
- OPRX Nasdaq
- Market Cap
- VTYX 154.9M
- OPRX 154.9M
- IPO Year
- VTYX 2021
- OPRX N/A
- Fundamental
- Price
- VTYX $1.70
- OPRX $12.14
- Analyst Decision
- VTYX Buy
- OPRX Buy
- Analyst Count
- VTYX 4
- OPRX 8
- Target Price
- VTYX $11.33
- OPRX $10.38
- AVG Volume (30 Days)
- VTYX 1.5M
- OPRX 329.8K
- Earning Date
- VTYX 05-08-2025
- OPRX 05-12-2025
- Dividend Yield
- VTYX N/A
- OPRX N/A
- EPS Growth
- VTYX N/A
- OPRX N/A
- EPS
- VTYX N/A
- OPRX N/A
- Revenue
- VTYX N/A
- OPRX $94,365,000.00
- Revenue This Year
- VTYX N/A
- OPRX $13.85
- Revenue Next Year
- VTYX N/A
- OPRX $11.15
- P/E Ratio
- VTYX N/A
- OPRX N/A
- Revenue Growth
- VTYX N/A
- OPRX 20.66
- 52 Week Low
- VTYX $0.78
- OPRX $3.78
- 52 Week High
- VTYX $5.66
- OPRX $12.78
- Technical
- Relative Strength Index (RSI)
- VTYX 61.97
- OPRX 62.53
- Support Level
- VTYX $1.68
- OPRX $11.27
- Resistance Level
- VTYX $1.85
- OPRX $12.77
- Average True Range (ATR)
- VTYX 0.15
- OPRX 1.07
- MACD
- VTYX 0.04
- OPRX 0.04
- Stochastic Oscillator
- VTYX 67.05
- OPRX 82.61
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.